Glomerulonephritis Market Segmentation along with Regional Outlook, Competitive Strategies, Factors Contributing to Growth and Forecast 2026

Global Glomerulonephritis Market is expected to grow at a substantial CAGR in the forecast period of 2019-2026.  The emergence of drugs used in kidney diseases, development of newer technologies, and vulnerable kidney disease patients enhancing the market growth. Global Glomerulonephritis Market By Therapy Type (Corticosteroids, ACE inhibitors, Diuretics, immunosuppressant, Angiotensin II receptors blockers, cyclophosphamide, atorvastatin others), Type (Acute and Chronic), Route of administration (Oral), End- users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Forecast to 2026

Get a Sample Report Now @

Glomerulonephritis is a serious inflammation and damage of glomeruli, resulting in kidney failure. Glomerulonephritis can grow suddenly or slowly, over the time.

According to the published article in Renal and Urology news, 2014, it was identified that from year 2007 to 2011, Among 13,712,946 enrolled patient there were 9,575 cases of primary GN and 7,176 cases of GN resulting from systemic immunologic disease. This significant rise in patient number acts as a driver for the market growth.

Key Market Players: Global Glomerulonephritis Market

Few of the major competitors currently working in the cystic fibrosis market are

  • Achillion Pharmaceuticals, Inc. (US),
  • Anthera Pharmaceuticals, Inc. (US),
  • Biogen Inc. (US),
  • Bristol-Myers Squibb Company (US),
  • Cellmid Ltd. (Australia),
  • ChemoCentryx, Inc. (US),
  • (US),
  • Dimerix ( Australia),
  • GlaxoSmithKline Plc (UK),
  • Merck KGaA (Germany),
  • Omeros Corporation (US),
  • Pfizer Inc. (US),
  • Calliditas Therapeutics AB (Sweden),
  • Ra Pharmaceuticals, Inc. (US),
  • Retrophin, Inc. (US),
  • Rigel Pharmaceuticals Inc. (US),
  • Takeda Pharmaceutical Company Limited (Japan),
  • Otsuka Pharmaceuticals Co., Ltd (Japan),
  • Hoffmann-La Roche Ltd (Switzerland),
  • Achillion Pharmaceuticals, Inc. (US),
  • Recordati S.p.A (Italy) and among others.

Market Drivers

  • Increase in prevalence rate of kidney disorders worldwide.
  • Rising awareness about glomerulonephritis therapy and technological advancement is driving the growth of market.
  • Increase in the rate of R&D initiatives is driving glomerulonephritis therapeutics market.

Market Restraints

  • High cost involved in the treatment.
  • Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market.
  • Lack of awareness among the patient and physician about glomerulonephritis treatment.

Key Developments in the Market:

  • In April 2019, Recordati S.p.A seeks Health Canada approval for cystagon which is manufactured by Mylan N.V for the treatment of rare kidney diseases.
  • In Jan 2019, Achillion Pharmaceuticals, Inc. a novel drug molecule ACH-0144471 has in Phase II trial in 20 patients with glomerulonephritis to evaluate the efficacy of the treatment. It is expect to complete by May 2020.

For Detailed TOC Global Glomerulonephritis Market Report @

Segmentation: Global Glomerulonephritis Market

By Type

  • Acute
  • Chronic

By Therapy Type

  • Corticosteroids
  • ACE inhibitors
  • Diuretics
  • immunosuppressant
  • Angiotensin II receptors blockers
  • Cyclophosphamide
  • atorvastatin
  • Others

By Treatment

  • Medication
  • Kidney Transplantation
  • Dialysis
  • Plasma exchange
  • Dietary changes
  • Avoid smoking

By Route of administration

  • Oral
  • Injectable

By End users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America
    • US.
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific
  • Middle East & Africa
    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Competitive Analysis: Global Glomerulonephritis Market

Global glomerulonephritis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of glomerulonephritis market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

  • Current and future of global glomerulonephritis market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Order a Copy of This Research Report @

About Data Bridge Market Research 14384 Articles
Hi, I am Ravi Kumar, a Blogger, Freelancer, SEO Consultant, an Internet Marketer, I am a research analyst who loves to evaluate data relating to Manufacturing industry, Management of companies and enterprises, Finance and insurance, Wholesale trade, Management, scientific, and technical consulting services

Leave a Reply

Your email address will not be published.